Janssen Products LP v. Evenus Pharmaceuticals Laboratories Inc

CourtCourt of Appeals for the Third Circuit
DecidedOctober 26, 2023
Docket22-2426
StatusPublished

This text of Janssen Products LP v. Evenus Pharmaceuticals Laboratories Inc (Janssen Products LP v. Evenus Pharmaceuticals Laboratories Inc) is published on Counsel Stack Legal Research, covering Court of Appeals for the Third Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Janssen Products LP v. Evenus Pharmaceuticals Laboratories Inc, (3d Cir. 2023).

Opinion

PRECEDENTIAL

UNITED STATES COURT OF APPEALS FOR THE THIRD CIRCUIT ___________

No. 22-2426 ___________

JANSSEN PRODUCTS, L.P.; PHARMA MAR, S.A., Appellants

v.

EVENUS PHARMACEUTICALS LABORATORIES INC.; JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. ___________

On Appeal from the United States District Court for the District of New Jersey (D.C. Civil No. 1-22-cv-02499) District Judge: Honorable Georgette Castner ___________ Argued June 14, 2023

Before: PORTER, FREEMAN, and FISHER, Circuit Judges.

(Opinion filed: October 17, 2023) ___________ Roy T. Englert, Jr. [ARGUED] Shikha Garg Kramer Levin Naftalis & Frankel 2000 K Street NW 4th Floor Washington, DC 20006

Peter C. Harvey Patterson Belknap Webb & Tyler 1133 Avenue of the Americas New York, NY 10036

Lisa Kobialka Kramer Levin Naftalis & Frankel 333 Twin Dolphin Drive Suite 700 Redwood Shores, CA 94065

Irena Royzman Daniel I. Sugarman Christine Willgoos Kramer Levin Naftalis & Frankel 1177 Avenue of the Americas New York, NY 10036 Counsel for Appellants

Arnold B. Calmann Katherine A. Escanlar Saiber 18 Columbia Turnpike Suite 200 Florham Park, NJ 07932

2 Clifton S. Elgarten Ali H. K. Tehrani Crowell & Moring 1001 Pennsylvania Avenue NW Washington, DC 20004

James K. Stronski [ARGUED] Crowell & Moring 590 Madison Avenue 20th Floor New York, NY 10022 Counsel for Appellees ___________

OPINION OF THE COURT ___________

FREEMAN, Circuit Judge.

Plaintiff pharmaceutical companies sued two competitors for misappropriation of trade secrets. While discovery was underway, plaintiffs moved ex parte for an order seizing some of defendants’ property. The District Court declined to order a seizure, concluding that plaintiffs did not satisfy the requirements for that extraordinary form of relief available under the Defend Trade Secrets Act, 18 U.S.C. § 1836. Plaintiffs appealed. Because the District Court’s order does not qualify for immediate appellate review, we will dismiss the appeal for lack of jurisdiction.

3 I

Appellants Janssen Products, L.P. and Pharma Mar, S.A. (together, “Janssen”) spent ten years and over half a billion dollars developing a stable, injectable version of the cancer drug trabectedin.1 They documented how to produce the drug for treatment on a commercial scale and patented some of the processes. They kept their data, specifications, and methods for manufacturing the drug confidential, and they consider that information trade secrets. The final drug product they developed is trademarked and sold as Yondelis.

In 2015, the U.S. Food and Drug Administration (“FDA”) approved Yondelis for use in certain cancer patients. Two years later, two competitors—Jiangsu Hengrui Pharmaceuticals Co. Ltd. (“Hengrui”), a Chinese corporation, and its U.S. subsidiary, eVenus Pharmaceuticals Laboratories, Inc. (“eVenus”)—sought FDA approval to sell a generic version of Yondelis. Janssen sued Hengrui and eVenus for patent infringement.

During discovery in the patent case, Janssen obtained documents that led them to believe Hengrui and eVenus misappropriated their trade secrets. In April 2022, they filed a separate lawsuit seeking relief under the Defend Trade Secrets Act, 18 U.S.C. § 1836 (“DTSA”), and state law.

The parties had a series of contentious discovery disputes in the patent case and the trade secrets case, and Janssen became convinced that Hengrui and eVenus had spoliated evidence. They filed an ex parte seizure application

1 We summarize the facts as alleged in Janssen’s complaint.

4 under the DTSA, which provides that “the court may, upon ex parte application but only in extraordinary circumstances, issue an order providing for the seizure of property necessary to prevent the propagation or dissemination of the trade secret that is the subject of the action.” 18 U.S.C. § 1836(b)(2)(A)(i).

In their ex parte application, Janssen asked the District Court to seize eVenus’s network servers and stored data, the laptops and cell phones of three current employees, and the laptop of one former employee. They argued that they satisfied all eight requirements for a DTSA ex parte seizure order. See 18 U.S.C. § 1836(b)(2)(A)(ii) (stating that the court cannot grant an application unless it “finds that it clearly appears from specific facts” that all enumerated requirements are satisfied). Per the DTSA’s requirement that a federal law enforcement officer carry out any seizure, Janssen proposed that the United States Marshals seize the property. 18 U.S.C. § 1836(b)(2)(E).

The District Court denied the ex parte seizure application after concluding that Janssen failed to make an adequate showing for five of the eight DTSA factors. It found that Janssen had not shown that eVenus was in actual possession of the property at issue, § 1836(b)(2)(A)(ii)(V), or that eVenus’s property was present at the location of the proposed seizure given questions about whether eVenus occupied the space, § 1836(b)(2)(A)(ii)(VI). It also found an insufficient showing of immediate and irreparable harm, § 1836(b)(2)(A)(ii)(II), or an immediate concern for spoliation, § 1836(b)(2)(A)(ii)(VII). Given that Janssen sought seizure of property that would sweep in “all [eVenus’s] company information,” “not limited in any way to the matters at issue in this case,” the Court found that the balance of harm weighed against granting the seizure. § 1836(b)(2)(A)(ii)(III).

5 Janssen timely appealed.

II

The District Court had jurisdiction under 28 U.S.C. §§ 1331 & 1332(a) and 18 U.S.C. § 1836(c). The parties dispute this Court’s jurisdiction. We always have jurisdiction to determine our own jurisdiction, United States v. Kwasnik, 55 F.4th 212, 215 (3d Cir. 2022), and our review is plenary, Ramara, Inc. v. Westfield Ins. Co., 814 F.3d 660, 665 (3d Cir. 2016).

III

Janssen contends that we have jurisdiction under 28 U.S.C. § 1292(a)(1) to review the order denying their DTSA ex parte seizure application. They argue that the District Court’s order is immediately appealable because the denial of a DTSA ex parte seizure is the denial of a functional injunction. They also assert that we have jurisdiction over DTSA ex parte seizure rulings for the same reasons that we have jurisdiction over Trademark Counterfeiting Act of 1984, 15 U.S.C. § 1116, (“Lanham Act”) ex parte seizure rulings. We are not persuaded and conclude that we lack jurisdiction under § 1292(a)(1). And because no other statute provides us jurisdiction, we will dismiss this appeal.

A

As a general rule, federal courts of appeals only have jurisdiction to review final decisions of the district courts. See Zurn Indus., LLC v. Allstate Ins. Co., 75 F.4th 321, 327 (3d Cir. 2023).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
Janssen Products LP v. Evenus Pharmaceuticals Laboratories Inc, Counsel Stack Legal Research, https://law.counselstack.com/opinion/janssen-products-lp-v-evenus-pharmaceuticals-laboratories-inc-ca3-2023.